{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001339","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.040606+00:00","generated_at":"2026-06-18T14:54:08.303221+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arbutus reports FY2022 net loss $69.5M, cash runway into Q4 2024; pipeline milestones set for 2023","bullets":["Net loss $69.5M ($0.46/share) vs $88.4M in 2021; revenue $39M up from $11M on Qilu license.","Cash $184.3M; expects net cash burn $95-100M in 2023, runway into Q4 2024.","AB-729 Phase 2a data with IFN expected H1 2023; trial with VTP-300 + nivolumab amended.","Phase 1 trials for oral PD-L1 AB-101 and RNA destabilizer AB-161 to start H1 2023; data H2 2023.","AB-343 (M pro inhibitor) Phase 1 expected H2 2023; discontinued AB-729+vebicorvir trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001339","json":"https://secwatch.observer/filing/0001171843-23-001339.json","markdown":"https://secwatch.observer/filing/0001171843-23-001339.md","text":"https://secwatch.observer/filing/0001171843-23-001339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323001339/0001171843-23-001339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323001339/f8k_030223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T14:54:08.303221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dae18baaa9ddbbda6acc22b2798fdefd7653f7ae","claim":"Arbutus Biopharma Corp reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 2, 2023, Arbutus Biopharma Corporation (the \"Company\") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022 and certain other information.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323001339/0001171843-23-001339-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}